Sign In
Buy ABBV
$227.23
+2.30 (+1.02%)
At Close: Jun 05, 2026
AbbVie: Buy This Dividend King For A Growing Stream Of Income
04:28am, Friday, 01'st Jul 2022
Even with the current bear market, the S&P 500 index's current yield is too anemic to provide lifestyle stability for most income investors. AbbVie's 3.7% dividend yield is more than double that of th
Is Most-Watched Stock AbbVie Inc. (ABBV) Worth Betting on Now?
10:05am, Wednesday, 29'th Jun 2022
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Investors Need Not Be Alarmed by Drug Patent Expirations
04:02pm, Tuesday, 28'th Jun 2022
Investors who are sweating the loss of patent protection for some of Big Pharma's top-selling drugs should relax.
AbbVie Stock's Healthy Yield Makes it a High-Conviction Holding
12:10pm, Monday, 27'th Jun 2022
Between the dividend payouts and the potential price appreciation, ABBV stock could be a pharma-market winner in 2022. The post AbbVie Stock's Healthy Yield Makes it a High-Conviction Holding appeared
Is AbbVie About To Get A New Blockbuster Drug?
06:13am, Monday, 27'th Jun 2022
AbbVie recently applied for FDA approval of its advanced Parkinson's disease drug candidate. This could be huge considering it's set to lose market exclusivity of Humira.
3 Top Dividend Stocks for Generating Passive Income
05:57am, Sunday, 26'th Jun 2022
These stocks offer attractive dividends that investors should be able to count on.
Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip
11:07am, Thursday, 23'rd Jun 2022
A top retailer and a pharmaceutical giant both now boast dividends that yield more than 3%.
What Stocks to Invest Today? 3 Pharmaceutical Stocks To Watch
12:15pm, Wednesday, 22'nd Jun 2022
Could these pharmaceutical stocks be worth watching today?
AbbVie (ABBV) Files Qulipta sNDA for Chronic Migraine Prevention
11:35am, Wednesday, 22'nd Jun 2022
With the latest approval for chronic migraine prevention, AbbVie's(ABBV) Qulipta becomes the only CGRP receptor antagonist approved for a broad preventive treatment of migraine indication.
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Crohn's Disease
11:39am, Monday, 20'th Jun 2022
The FDA approval of AbbVie's (ABBV) Skyrizi for moderately to severely active Crohn's disease was supported by data from two phase III induction studies - ADVANCE, MOTIVATE, and one maintenance study
3 Dividend Stocks to Double Up on Right Now
11:00am, Saturday, 18'th Jun 2022
They're profitable, growing, hiking their payouts, and surviving the bear market without breaking a sweat.
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
10:49am, Thursday, 16'th Jun 2022
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
3 Dividend-Paying Stocks Vastly Outperforming the S&P 500
12:24pm, Tuesday, 14'th Jun 2022
With many investors focusing on the decline in the S&P 500, you might be surprised to know there are companies that are greatly outperforming the index. In some cases, certain stocks have seen a total
SPX now in bear market territory: these two stocks are still a buy
03:42pm, Monday, 13'th Jun 2022
The S&P 500 index down more than 20% for the year is an opportunity to position your long-term portfolio for remarkable profits, says the Chief Investment Officer of Pivotal Advisors. Reason to stay i
Consistent Clinical Results Indicate Upside for AbbVie Stock
12:11pm, Monday, 13'th Jun 2022
ABBV stock can move higher as it trades at a very reasonable valuation. Meanwhile, AbbVie's financials and dividend payments sweeten the deal.
